Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Recursion Pharmaceuticals, Inc.

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers EXAI RXRX
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers EXAI RXRX
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion Announces Plans to Open New Office in London
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.